BiotechTube

SOC +Posaconazole 18 MG/ML (milligram/milliliter)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Aspergillosis; Pulmonary, Invasive (Etiology)

Conditions

Aspergillosis; Pulmonary, Invasive (Etiology)

Trial Timeline

Dec 27, 2017 → Mar 30, 2021

NCT ID
NCT03378479

About SOC +Posaconazole 18 MG/ML (milligram/milliliter)

SOC +Posaconazole 18 MG/ML (milligram/milliliter) is a approved stage product being developed by Merck for Aspergillosis; Pulmonary, Invasive (Etiology). The current trial status is completed. This product is registered under clinical trial identifier NCT03378479. Target conditions include Aspergillosis; Pulmonary, Invasive (Etiology).

What happened to similar drugs?

7 of 15 similar drugs in Aspergillosis; Pulmonary, Invasive (Etiology) were approved

Approved (7) Terminated (6) Active (6)
✅MicafunginAstellas PharmaApproved
✅micafungin + voriconazoleAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅caspofunginMerckApproved
✅Ambisome + caspofunginGilead SciencesApproved
✅anidulafungin and voriconazolePfizerApproved
✅voriconazole + anidulafunginPfizerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03378479ApprovedCompleted

Competing Products

20 competing products in Aspergillosis; Pulmonary, Invasive (Etiology)

See all competitors
ProductCompanyStageHype Score
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 2
27
MicafunginAstellas PharmaApproved
35
isavuconazoleAstellas PharmaPhase 3
40
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
Isavuconazole + VoriconazoleAstellas PharmaPhase 3
40
micafungin + voriconazoleAstellas PharmaApproved
35
FK463Astellas PharmaPhase 2
35
MicafunginAstellas PharmaApproved
35
Olorofim + AmBisome®ShionogiPhase 3
44
Prednisolone + VoriconazoleCiplaPhase 2/3
38
Posaconazole + VoriconazoleMerckPhase 3
40
caspofunginMerckApproved
39
caspofungin acetateMerckPhase 2
35
MK0991, caspofungin acetate + Comparator: amphotericin B + Comparator: lipid formulation of amphotericin B and/or azoleMerckPhase 2
35
Posaconazole IV + Posaconazole PFS + Posaconazole tabletMerckPhase 2
35
AmBisomeGilead SciencesPhase 3
40
Ambisome + caspofunginGilead SciencesApproved
43
nebulised liposomal amphotericin BGilead SciencesPhase 2/3
38
Voriconazole + VoriconazolePfizerPhase 2
35
IsavuconazolePfizerPre-clinical
26